Microbial metabolite indole-3-propionic acid promotes mitochondrial respiration to suppress pro-inflammatory T cells, alleviating inflammatory bowel disease #IBD in humans and mice @h_sokol @NatMetabolism @Cyaner_Li @Inserm 🇫🇷 https://t.co/PbNg3CfnGW https://t.co/K98iiRd0xY

This is unfortunately quite common. How many doctors still eat ultra-processed foods on a regular basis? It’s do-able if it is a priority (I haven’t since 2008). Don’t let the profession destroy your health and be an example for your patients.

Here's the link to the system, try it! https://t.co/XS5o6Wsf9F @qedScience

BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 It started from my frustration with the depressing effect that the current publishing system has

It has been a long two years, albeit revelatory. But today I share in the simcha of my Israeli friends and am giving thanks like my Canadian friends.

And here are IBD-specific sites: https://t.co/orSCsyrjz1 https://t.co/nAIoFMXP21 https://t.co/eqYgEJqa0V https://t.co/EmPgf87238 https://t.co/0jQmwreBRC https://t.co/1wbx3ex3It

https://t.co/E578d9ClRg and her older site https://t.co/bWt3c2FvmL https://t.co/SRprthqBEb (especially the very vanilla cupcakes) https://t.co/L8y9rz5vDB https://t.co/G5WI37cTMp https://t.co/mmdvajGN0i https://t.co/TaE2VYuY2e https://t.co/kLePYOe1Z1 https://t.co/ID4hFUJLbK

Great thread 🍭🍪🍫🍩🧁🍦 No refined or processed sugar has been a cornerstone of our diet since 2017. Not “less”, none. Honey, dates, and fruit are sweet and nutritious and there are countless fantastic recipes for cakes, cookies, donuts, ice cream—whatever you can imagine,

The accepted dogma for dietary lipids was their absorption by the gut lining into our bloodstream. It turns out there's another way in, via our immune cells, influenced by the gut microbiome (as shown in mice) @ScienceMagazine https://t.co/Knvh8g9BjM https://t.co/15UXOG7tAI

Ultra-processed grains linked to elevated risk for IBD, especially ulcerative colitis ⁦@HealioGastro⁩ ⁦@NarulaNeeraj⁩

“The first time one of your children is seriously ill or hurt, you pass through a portal into a new world. Fear envelops you, but also transforms you. You learn to recognize fear in its purest form—hot and metallic. It sits on your chest like a breastplate, ignites pilot lights

IBD Research Community: study not only the sickest IBD patients but also the healthiest ones, those doing remarkably well with optimal objective long-term outcomes. Study those who have been unquestionably cured—whether surgically, medically, or without any medication—because

The proteins in our blood as fingerprints for 59 diseases and health @ScienceMagazine https://t.co/02MgtnDqp6

https://t.co/5mVbThnpRX https://t.co/89AcEcSLeK

Thinking about all kids (and adults) getting their regular infusion of microplastics. Can we please collectively do something to fix this? The pharmaceutical supply chain has other options. Beyond glass, there are modern non-PVC and non-DEHP containers offered by Baxter and ICU

It is not the first time this idea has been suggested and yet I find this hypothesis highly relevant for IBD patients ➡️ Losartan reduces inflammation and fibrosis and prevents relapse of fibrosis after steroid-induced remission, in mice prone to Crohn’s disease-like ileitis

And to be clear I agree. I think guidelines are mostly unhelpful for selecting therapy because of the limitations in clinical trials for selecting the right drugs for the right patients. NMAs should not be used to tier therapies especially by reimbursement bodies.

Dr. Brian Feagan speaking to a packed, sold-out audience discussing the utility of Vedolizumab in 2025 and reminds us that the Placebo treated group had a higher rate of adverse events than the patients on Vedo in trials. Important to remember that active disease in patients on

Amazing result A 21-yo woman with ulcerative colitis resistant to every tested therapy (prednisolone, mesalamine, infliximab, ustekinumab, ozanimod, filgotinib, vedolizumab, upadacitinib, cyclosporine + mirikizumab, and blinatumomab) CD19 CAR-T cells induced remission:

💡Are you interested in how to position and use p19 in clinical practice? @YOGI_IBD presents this fantastic overview where global young IBD leaders take the stage💃🏻 Join us tomorrow!!! 👇🏻👇🏻👇🏻 4 pm Central Europe Time ⏰ @JosephHabibi_MD 🥇